Antibody-Drug Conjugate Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

Sung-Soo Park2
MBrace Therapeutics1
Liaoning Cancer Hospital & Institute1

Indications

Cancer4
Relapsed/refractory High Grade B Cell Lymphoma1
Diffuse Large B Cell Lymphoma Relapsed1
Multiple Myeloma, Relapsed1
Breast Cancer Females1

Other3 trials

Immunotherapy in Lymphoma

Optimal Application Timing of ADC Drugs for Advanced Breast Cancer

Phase 2

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

San Francisco, California1 trial

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.